Bai Ze Medical (02609.HK) Hot Stock Analysis: Award Recognition and Expectation of Oversold Rebound

Bai Ze Medical (02609.HK) is a Hong Kong-listed company focusing on three major disciplines: oncology, traditional Chinese medicine, and rehabilitation [2], belonging to the medical and medical beauty services sector. Due to system time constraints, real-time data for January 1, 2026 cannot be obtained, so this analysis is based on public information as of December 25, 2025:

1. Industry Awards and Market Recognition
   : On December 25, 2025, the company and its CFO Mr. Yao Le won the Gelonghui “Annual Excellent Medical and Health Enterprise Award” and “Annual Excellent CFO Award” respectively, demonstrating the capital market’s recognition of its governance capabilities and the professionalism of its core team [1].
2. Stock Price and Trading Data
   : The stock price has dropped more than 50% cumulatively from its September 2025 high; on December 23, due to the expiration of the cornerstone investors’ lock-up period (about 35.3178 million shares unlocked), the intraday drop exceeded 6% [4]; on December 24, the closing price was HK$4.18, hitting a new listing low with a drop of 2.79%, a trading volume of 259,800 shares, and a transaction amount of HK$1.0949 million. Technical indicators show that the 10-day, 20-day, and 50-day moving averages are HK$4.362, HK$4.742, and HK$5.936 respectively, and the RSI14 is 28.451, entering the oversold range [3].
3. Industry Resources and Advantages
   : The company cooperated with Peking University Cancer Hospital to build Beijing West Oncology Hospital and has a strategic cooperation with the team of academician Shi Xuemin, a national medical master, possessing strong industry resources and professional advantages in the oncology medical services field [2].

1. Brand Repair Potential Supported by Awards
   : The Gelonghui awards are not only a recognition of the company’s governance and team but also may enhance its brand influence in the oncology medical services field, laying the foundation for the recovery of long-term investors’ confidence [1].
2. Oversold Signal and Short-term Rebound Expectation
   : The oversold state with RSI14 below 30 indicates high short-term downward pressure on the stock price, but historical data shows that technical rebounds often follow such states [3].
3. Track Growth and Resource Barriers
   : The demand for oncology medical services grows steadily, and the company’s cooperation with well-known medical institutions and expert teams forms certain industry barriers, possessing long-term development potential [2].

• Main Risks
  :
  • Price volatility risk: The recent sharp drop in stock price leads to high volatility; further downward possibility needs to be警惕 [3][4];
  • Lock-up expiration pressure: The existence of a large number of unlocked shares may continue to suppress the stock price [4];
  • Industry competition risk: The medical services industry is highly competitive; the company needs to continuously improve its core competitiveness to maintain its market position [2].
• Potential Opportunities
  :
  • Increased investor attention driven by award recognition;
  • Short-term technical rebound opportunities brought by the oversold state;
  • Long-term growth space of the oncology medical services track [1][3][2].

Bai Ze Medical (02609.HK) is a Hong Kong-listed oncology medical services enterprise with important cooperation resources in the industry; on December 25, 2025, the company and its CFO won industry awards issued by Gelonghui, gaining capital market recognition; the stock price has dropped more than 50% from its September 2025 high, hitting a new listing low of HK$4.18 on December 24, and is in the oversold range; the cornerstone investors’ lock-up period expired on December 23, 2025, and subsequent selling pressure needs to be关注; currently, real-time trading data for January 1, 2026 cannot be obtained temporarily.